| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
45,467 |
39,409 |
$3.14M |
| 90791 |
Psychiatric diagnostic evaluation |
15,832 |
13,814 |
$2.85M |
| T1016 |
Case management, each 15 minutes |
94,043 |
31,782 |
$2.64M |
| H0047 |
Alcohol and/or other drug abuse services, not otherwise specified |
2,697 |
2,269 |
$1.70M |
| 90837 |
Psychotherapy, 53 minutes with patient |
16,383 |
7,706 |
$1.59M |
| S9480 |
Intensive outpatient psychiatric services, per diem |
10,798 |
2,957 |
$1.27M |
| 90833 |
Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) |
22,945 |
20,215 |
$853K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
5,747 |
4,205 |
$704K |
| H2017 |
Psychosocial rehabilitation services, per 15 minutes |
7,958 |
1,889 |
$644K |
| 90792 |
Psychiatric diagnostic evaluation with medical services |
7,757 |
6,765 |
$596K |
| T2001 |
Non-emergency transportation; patient attendant/escort |
54,735 |
15,278 |
$573K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
18,343 |
12,449 |
$538K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
12,104 |
10,763 |
$528K |
| Q3014 |
Telehealth originating site facility fee |
20,280 |
14,714 |
$432K |
| H0015 |
Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education |
2,345 |
649 |
$388K |
| H2014 |
Skills training and development, per 15 minutes |
5,538 |
1,419 |
$222K |
| H0031 |
Mental health assessment, by non-physician |
1,590 |
1,356 |
$219K |
| 99215 |
Prolong outpt/office vis |
2,064 |
1,872 |
$180K |
| 99490 |
Ccm add 20min |
6,798 |
6,339 |
$162K |
| H0002 |
Behavioral health screening to determine eligibility for admission to treatment program |
4,841 |
4,600 |
$139K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
3,147 |
1,963 |
$111K |
| 90834 |
Psychotherapy, 45 minutes with patient |
1,433 |
1,051 |
$97K |
| 90832 |
Psychotherapy, 30 minutes with patient |
1,857 |
1,240 |
$93K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,012 |
1,748 |
$87K |
| H0001 |
Alcohol and/or drug assessment |
507 |
481 |
$68K |
| H0010 |
Alcohol and/or drug services; sub-acute detoxification (residential addiction program inpatient) |
391 |
199 |
$62K |
| 90853 |
Group psychotherapy (other than of a multiple-family group) |
2,081 |
1,023 |
$57K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
3,231 |
2,570 |
$55K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
893 |
642 |
$52K |
| H0004 |
Behavioral health counseling and therapy, per 15 minutes |
375 |
169 |
$41K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,815 |
2,072 |
$39K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
413 |
394 |
$36K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,315 |
1,154 |
$32K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
427 |
395 |
$31K |
| 99309 |
Subsequent nursing facility care, per day, low to moderate complexity |
330 |
149 |
$28K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
359 |
342 |
$24K |
| 90839 |
|
236 |
214 |
$24K |
| G0444 |
Annual depression screening, 5 to 15 minutes |
2,034 |
1,798 |
$19K |
| 80306 |
|
1,467 |
986 |
$17K |
| 99386 |
|
226 |
206 |
$17K |
| 82075 |
|
2,202 |
1,654 |
$16K |
| 99385 |
|
241 |
205 |
$13K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
648 |
351 |
$12K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
297 |
274 |
$11K |
| 86580 |
|
2,848 |
2,531 |
$11K |
| 99233 |
Prolong inpt eval add15 m |
78 |
17 |
$8K |
| 80305 |
|
1,351 |
1,139 |
$7K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
460 |
416 |
$7K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
443 |
402 |
$7K |
| H0035 |
Mental health partial hospitalization, treatment, less than 24 hours |
133 |
13 |
$6K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
31 |
26 |
$2K |
| 99201 |
|
131 |
108 |
$2K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
43 |
37 |
$1K |
| G0442 |
Annual alcohol misuse screening, 5 to 15 minutes |
123 |
83 |
$1K |
| 87102 |
|
288 |
233 |
$1K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
16 |
15 |
$1K |
| 90674 |
|
58 |
48 |
$998.88 |
| 90686 |
|
71 |
65 |
$955.47 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
68 |
63 |
$884.54 |
| 81025 |
|
213 |
181 |
$751.68 |
| H0034 |
Medication training and support, per 15 minutes |
34 |
17 |
$560.34 |
| H0007 |
Alcohol and/or drug services; crisis intervention (outpatient) |
21 |
18 |
$434.20 |
| H0049 |
Alcohol and/or drug screening |
49 |
36 |
$399.75 |
| Q0091 |
Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory |
12 |
12 |
$236.88 |
| 98967 |
|
181 |
165 |
$45.14 |
| 99422 |
|
191 |
155 |
$36.69 |
| J1071 |
Injection, testosterone cypionate, 1 mg |
438 |
241 |
$27.71 |
| G2012 |
Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion |
18 |
18 |
$2.29 |
| J2315 |
Injection, naltrexone, depot form, 1 mg |
57 |
52 |
$0.01 |
| 3079F |
|
127 |
117 |
$0.00 |
| 3008F |
|
1,675 |
1,545 |
$0.00 |
| 3074F |
|
214 |
194 |
$0.00 |
| 3080F |
|
243 |
218 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
266 |
248 |
$0.00 |
| 99407 |
|
95 |
82 |
$0.00 |
| T2022 |
Case management, per month |
106 |
106 |
$0.00 |
| 99000 |
|
102 |
91 |
$0.00 |
| 99406 |
|
71 |
64 |
$0.00 |
| 3075F |
|
15 |
12 |
$0.00 |
| G0506 |
Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service) |
46 |
43 |
$0.00 |
| 3015F |
|
215 |
207 |
$0.00 |
| 3725F |
|
1,841 |
1,692 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
918 |
856 |
$0.00 |
| 99423 |
|
17 |
14 |
$0.00 |
| 3077F |
|
391 |
365 |
$0.00 |
| 3078F |
|
255 |
236 |
$0.00 |
| G0476 |
Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test |
209 |
198 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
13 |
12 |
$0.00 |
| J2426 |
Injection, paliperidone palmitate extended release (invega sustenna), 1 mg |
16 |
13 |
$0.00 |
| 99421 |
|
34 |
28 |
$0.00 |